Drilldown: Medicines

Adalimumab (1) · Linagliptin (1) · Sitagliptin (1)

Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Januvia; with metformin Janumet/Janumet XR (1) · Tradjenta; with metformin Jentadueto (1)

[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) · [[:Category:Biologics|Biologic]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) · [[:Category:Immunosuppressants|Immunosuppressant]] (1) · [[:Category:Incretin_modulators|Incretin pathway modulator]] (2) · [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) · [[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)

None (1) · '"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)

None (1) · '"`UNIQ--vote-00000764-QINU`"' (1) · '"`UNIQ--vote-0000117B-QINU`"' (1)

100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1)

25, 50, 100 mg tablets; combination tablets with metformin (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) · 5 mg tablets; combination with metformin (1)

100 mg/d (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 5 mg/d (1)

Oral (2) · Subcutaneous (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

2 weeks per dose (1) · 24 hours (2)

~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)

~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)

None (1) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2)

None (1) · [[USLegal:Prescription only|Rx-only]] in US (2)